Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes

Leticia Cuarental, Lara Valiño-Rivas, Luis Mendonça, Moin Saleem, Sergio Mezzano, Ana Belen Sanz, Alberto Ortiz*, Maria Dolores Sanchez-Niño*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

10 Citations (Scopus)
46 Downloads (Pure)


Primary membranous nephropathy is usually caused by antibodies against the podocyte antigen membrane M-type phospholipase A2 receptor (PLA2R). The treatment of membranous nephropathy is not fully satisfactory. The calcineurin inhibitor tacrolimus is used to treat membranous nephropathy, but recurrence upon drug withdrawal is common. TNF superfamily members are key mediators of kidney injury. We have now identified key TNF receptor superfamily members in podocytes and explored the regulation of PLA2R expression and the impact of tacrolimus. Data mining of single cell transcriptomics and glomerular transcriptomics data identified TNFRSF12a/Fn14 as the highest expressed TNF receptor superfamily gene in human membranous nephropathy, and this was confirmed by immunohistochemistry that also identified NFκB activation in membranous nephropathy podocytes. Additionally, glomerular transcriptomics identified PLA2R1 expression as being increased in membranous nephropathy in the parenteral administration of the Fn14 ligand TWEAK increased podocyte PLA2R expression in mice. Furthermore, in cultured human podocytes, TWEAK increased the expression of PLA2R as well as the expression of other genes recently identified by GWAS as linked to membranous nephropathy: NFKB1 and IRF4. Interestingly, IRF4 encodes the FK506-binding protein 52 (FKBP52), a protein associated with tacrolimus. Tacrolimus prevented the increased expression of PLA2R, NFKB1 and IRF4 induced by TWEAK in cultured podocytes. In conclusion, TWEAK upregulates the expression of PLA2R and of other genes linked to membranous nephropathy in podocytes, and this is prevented by tacrolimus. An impact of tacrolimus on the expression of PLA2R and other genes in podocytes may underlie its efficacy in treating the disease as well as the frequent recurrence of nephrotic syndrome upon tacrolimus withdrawal.

Original languageEnglish
Article number2178
Number of pages13
JournalJournal of Clinical Medicine
Issue number7
Publication statusPublished - 10 Jul 2020


  • podocyte
  • nephrotic syndrome
  • membranous nephropathy
  • Fn14
  • tacrolimus
  • PLA2R


Dive into the research topics of 'Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes'. Together they form a unique fingerprint.

Cite this